Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:02 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Patients With Relapsed Ovarian Cancer (2nd and 3rd Line) Treated With Chemotherapy According to AGO Guidelines
NCT03622931 · Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH · PHASE2 · terminated · last registry update 2021-02-08 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “due to lack of recruitment” | – | Registry record, Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MPL within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-02-02Phase 3 first posted: AO GENERIUM, GNR-069 + Nplate (NCT05220878)
- 2021-12-09Also stopped (withdrawn): Ayman Saad, Avatrombopag (NCT04312789)
- 2021-11-24Results posted on the registry: Sobi, Inc., Avatrombopag + Placebo Oral Tablet (NCT03471078)
- 2021-10-22Also stopped (withdrawn): Sobi, Inc., Avatrombopag 20 mg Oral Tablet (NCT05046327)
- 2021-09-21Results posted on the registry: M.D. Anderson Cancer Center, AMG 531 + Rituximab (NCT00299182)
- 2021-09-16Phase 3 first posted: Sobi, Inc., Avatrombopag 20 mg Oral Tablet (NCT05046327)
- 2021-08-05Results posted on the registry: Abramson Cancer Center at Penn Medicine, Eltrombopag (NCT01113502)
- 2021-08-05Also stopped (terminated): Abramson Cancer Center at Penn Medicine, Eltrombopag (NCT01113502)
- 2021-07-14Phase 3 first posted: Jiangsu HengRui Medicine Co., Ltd., Hetrombopag Olamine + Placebo (NCT04961710)
- 2021-06-07Phase 3 first posted: Institute of Hematology & Blood Diseases Hospital, China, Combined use of TPO-RAs with low-dose anti-CD20 antibody + The best available therapy (NCT04915482)
- 2021-03-18Also stopped (terminated): Shionogi, Placebo + Lusutrombopag (NCT01054443)
- 2021-02-26Results posted on the registry: Shionogi, Lusutrombopag (NCT01129024)
- 2021-02-26Also stopped (terminated): Shionogi, Lusutrombopag (NCT01129024)
- 2021-02-24Results posted on the registry: Shionogi, Placebo + Lusutrombopag (NCT01054443)
- 2021-02-15Results posted on the registry: Kyowa Kirin Korea Co., Ltd., AMG531 (NCT02094417)
- 2021-01-28Phase 3 first posted: Peking Union Medical College Hospital, Avatrombopag 20 MG (NCT04728789)
- 2020-12-08Also stopped (withdrawn): Memorial Sloan Kettering Cancer Center, Avatrombopag (NCT04437953)
- 2020-11-24Results posted on the registry: Case Comprehensive Cancer Center, eltrombopag olamine (NCT02071901)
- 2020-11-03Also stopped (terminated): PrECOG, LLC., Phase I- Cytarabine & Eltrombopag + Phase II- Sequence A (NCT01656252)
- 2020-08-18Phase 3 first posted: Sobi, Inc., Avatrombopag + Placebo (NCT04516967)
- 2020-06-05Results posted on the registry: National Heart, Lung, and Blood Institute (NHLBI), Cohort 1: hATG, CsA, EPAG Day 14 to Month 6 + Cohort 2: hATG, CsA, EPAG Day 14 to Month 3 (NCT01623167)
- 2020-04-15Results posted on the registry: Sobi, Inc., Avatrombopag 60 mg (NCT03326843)
- 2020-04-15Also stopped (terminated): Sobi, Inc., Avatrombopag 60 mg (NCT03326843)
- 2020-02-18Results posted on the registry: M.D. Anderson Cancer Center, Eltrombopag + Hypomethylating Agent (HMA) (NCT01893372)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision